Immune Therapeutics, Inc. Appoints John H. Abeles, M.D. as Chairman and CEO of Company’s Subsidiary, Cytocom, Inc. and as Senior Adviser to Immune Therapeutics, Inc.
23. August 2017 09:04 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., Aug. 23, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN) today announced that it has appointed John H. Abeles, M.D. as Chairman and CEO of its subsidiary, Cytocom,...
Immune Therapeutics Signs Memorandum of Understanding for Distribution of Lodonal™ in Côte d’Ivoire and acquires COPP for Côte d’Ivoire; Company Plans for Approval of Lodonal in Côte d’Ivoire in 2017
31. Mai 2017 09:14 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., May 31, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a specialty pharmaceutical company focused on developing and commercializing our novel patented, affordable,...
CORRECTING and REPLACING: Immune Therapeutics, Inc.
22. Mai 2017 09:24 ET
|
Immune Therapeutics, Inc.
In a release issued under the same headline earlier today by Immune Therapeutics, Inc. (OTCQB:IMUN), the headline has been corrected to read "Immune Therapeutics Announces NAFDAC Approval...
Immune Therapeutics Announces NAFDAC Approval of Lodonal™ for the Treatment of HIV in Nigeria
22. Mai 2017 08:42 ET
|
Immune Therapeutics, Inc.
Highlights: National Agency for Food and Drug Administration and Control (“NAFDAC”) approval paves way for Immune Therapeutics’ first significant revenue channel Immune Therapeutics’ goal to capture...
Immune Therapeutics, Inc. Files Lodonal New Drug Application in Kenya
25. April 2017 11:37 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., April 25, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM...
Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya
17. April 2017 11:44 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., April 17, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM,...
Immune Therapeutics, Inc. Strengthens Balance Sheet With Debt Settlement
12. April 2017 13:36 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., April 12, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM,...
Immune Therapeutics, Inc. Announces Expansion of Patent Portfolio
30. März 2017 09:45 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., March 30, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using LodonalTM,...
Immune Therapeutics Clears Critical Regulatory Hurdle for Lodonal in Kenya
17. März 2017 09:07 ET
|
Immune Therapeutics, Inc.
ORLANDO, Fla., March 17, 2017 (GLOBE NEWSWIRE) -- Immune Therapeutics, Inc. (OTCQB:IMUN), a clinical-stage biopharmaceutical company developing therapies for a range of conditions using Lodonal™,...
Immune Therapeutics, Inc. Further Strengthens Balance Sheet as it Prepares for Commercialization
15. März 2017 14:59 ET
|
Immune Therapeutics, Inc.
Highlights: Company Redeems Nearly All Outstanding Convertible DebenturesReplaces Nearly $650,000 of Long-Term Debt with Financing on Significantly Better Terms from a Strategic Long-Term...